Compare Matson Inc (MATX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Zoetis Inc — how do they compare? Matson Inc trades at $214.64 (market cap $6.11B), while Zoetis Inc trades at $73.6 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 5.1× Matson Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| MATX | ZTS | |
|---|---|---|
Market Cap | $6.11B | $31.14B |
Sector | Technology | Health |
52-Week High | $223.55 | $156.76 |
52-Week Low | $88.05 | $71.91 |
Enterprise Value | $6.71B | $38.70B |
Dividend Yield | 0.74% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $214.52, up 2.8% today, with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, a 13.41% net margin, and robust cash flow generation. Recent Q2 2026 results exceeded expectations with EPS of $4.27 versus $3.79 estimate, driving positive analyst sentiment.
Outlook remains positive with 27% upside to consensus target of $265. Key risks include shipping industry cyclicality and global trade volatility. The combination of strong earnings momentum, attractive valuation at 13.79 P/E, and institutional support supports a constructive investment case for the stock.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
